News and Announcements
DataBench Secures 100% Subscription in SAFE Note Round, Raises £500,000 and Invites Investors to Join in Upcoming Seed ‘3’ Round
- Published January 27, 2023 5:15AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
DataBench, a cutting-edge technology company, is thrilled to announce that it has received a 100% subscription in its recent SAFE Note round, raising an impressive £500,000 from its existing shareholders. This funding will ensure a fully funded runway for the company as it looks to onboard its first customers in early 2023.
According to Ben Cameron, Non-Executive Director and Co-Founder of DataBench, “It is incredibly encouraging to see our existing shareholders so deeply engaged and invested in our journey. To achieve full subscription during the busy holiday season is a testament to the strength of our company and our plans for the future.”
As DataBench looks forward to 2023, the company plans to launch a Seed ‘3’ fundraising event, offering investors the opportunity to join DataBench on its journey to success. To register interest in this upcoming round and receive a copy of the Information Memorandum, please visit DataBench’s website www.databench.com.au or visit the DataBench Wholesale Investor deal room for more information. Don’t miss out on this exciting opportunity to be a part of the DataBench family and invest in the future of cutting-edge technology.
Connect with the company and learn more about DataBench by accessing their deal room here.
Company Updates
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
